Strategies for Targeting IL-4 as a Novel Therapeutic Approach for the Treatment of Atopic Dermatitis

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)

Volume 16, 3 Issues, 2017

Download PDF Flyer

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Claudiu T. Supuran
Neurofarba Department
University of Florence

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Strategies for Targeting IL-4 as a Novel Therapeutic Approach for the Treatment of Atopic Dermatitis

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 1(1): 41-53.

Author(s): H. Hennekes and K Asadullah.

Affiliation: Corporate Project Management Therapeutics, Schering-AG, 13342 Berlin, Germany


Atopic dermatitis (AD) is a chronic inflammatory skin disease, affecting more than 10% of children. It frequently predates the development of allergic rhinitis or asthma and is often difficult to treat. The current therapeutic options are limited, might induce side effects, and are not curative, indicating the need for better drugs. Numerous studies demonstrated the complex interrelationship of genetic, environmental, psychologic, skin barrier, and immunologic factors that contribute to the development and severity of AD. Today, AD is considered to be a T-cell mediated dermatosis, in which cytokines play a crucial role. These insights provide new opportunities for targeted therapeutic intervention. One target candidate is the T-helper (Th)-2 cytokine interleukin (IL)-4. Here we review the rationale and the current strategies for targeting IL-4, which might lead to novel therapies for atopic dermatitis and other atopic disorders. This includes the development of i) inhibitors of IL-4 formation, ii ) soluble IL- 4 receptors, iii) IL-4 receptor antagonists and iv) inhibitors of IL-4 signal transduction. The approaches followed in these areas, their current status and their advantages and disadvantages are discussed.


IL-4, atopic dermatitis, receptor antagonists.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 1
Issue Number: 1
First Page: 41
Last Page: 53
Page Count: 13
DOI: 10.2174/1568014024606520

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science